NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Monday that revenues for its Fiscal Year 2012 fourth quarter increased 2 percent year over year.

Total revenues for the three months ended Oct. 31 rose to $1.77 billion from $1.73 billion a year ago, edging out the average analyst estimate of $1.76 billion. Orders during the quarter were flat at $1.75 million.

"The headline for this quarter is that most of our end markets remained soft," Agilent CEO Bill Sullivan said on a conference call after the release of the company's earnings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.